NeuroBo Pharmaceuticals Statistics
Share Statistics
NeuroBo Pharmaceuticals has 8.62M
shares outstanding. The number of shares has increased by 51.98%
in one year.
| Shares Outstanding | 8.62M |
| Shares Change (YoY) | 51.98% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 4.59% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | n/a |
| FTD / Avg. Volume | n/a |
Short Selling Information
The latest short interest is 34.27K, so 0.4% of the outstanding
shares have been sold short.
| Short Interest | 34.27K |
| Short % of Shares Out | 0.4% |
| Short % of Float | 1.06% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -1.5 and the forward
PE ratio is null.
NeuroBo Pharmaceuticals's PEG ratio is
0.02.
| PE Ratio | -1.5 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 1.12 |
| P/FCF Ratio | -1.73 |
| PEG Ratio | 0.02 |
Financial Ratio HistoryEnterprise Valuation
NeuroBo Pharmaceuticals has an Enterprise Value (EV) of -3.48M.
| EV / Sales | 0 |
| EV / EBITDA | 0.22 |
| EV / EBIT | 0.32 |
| EV / FCF | 0.32 |
Financial Position
The company has a current ratio of 3.78,
with a Debt / Equity ratio of 0.
| Current Ratio | 3.78 |
| Quick Ratio | 3.78 |
| Debt / Equity | 0 |
| Debt / EBITDA | -0.01 |
| Debt / FCF | -0.02 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is -74.74% and Return on Invested Capital is -94.83%.
| Return on Equity | -74.74% |
| Return on Assets | -54.74% |
| Return on Invested Capital | -94.83% |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,558,750 |
| Employee Count | 8 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by null% in the
last 52 weeks. The beta is -0.28, so NeuroBo Pharmaceuticals's
price volatility has been lower than the market average.
| Beta | -0.28 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 2.49 |
| 200-Day Moving Average | 3.52 |
| Relative Strength Index (RSI) | 26.03 |
| Average Volume (20 Days) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -15.89M |
| Net Income | -12.47M |
| EBITDA | -15.88M |
| EBIT | -15.89M |
| Earnings Per Share (EPS) | -2.46 |
Full Income StatementBalance Sheet
The company has 22.43M in cash and 203K in
debt, giving a net cash position of 22.23M.
| Cash & Cash Equivalents | 22.43M |
| Total Debt | 203K |
| Net Cash | 22.23M |
| Retained Earnings | -108.27M |
| Total Assets | 22.15M |
| Working Capital | 12.82M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -10.8M
and capital expenditures -50K, giving a free cash flow of -10.85M.
| Operating Cash Flow | -10.8M |
| Capital Expenditures | -50K |
| Free Cash Flow | -10.85M |
| FCF Per Share | -2.14 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
